Want to see SNDL full AI Analyst Report?

SNDL (SNDL) Earnings Dates, Call Summary & Reports

6,242 Followers

Earnings Data

Report Date

Aug 07, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

>-0.01

Last Year’s EPS

<0.01

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 2 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Apr 29, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call mixed clear operational and market challenges—most notably declines in net revenue (-4.4% YoY), a sharp drop in cannabis operations revenue (-14%) and compressed margins—with several credible strategic responses: an exclusive Jeter brand deal, retail margin improvements, a profit enhancement program expected to yield >$20M in incremental operating income, active share repurchases and constructive U.S. regulatory developments. Near-term cash flow and inventory/working-capital issues are material, but management has delineated remediation actions and efficiency levers that could materially improve results later in the year.

Company Guidance

Management guided that they expect revenue growth to improve year‑over‑year through 2026 (as they lap softer comps in H2) and that profit‑enhancement actions—pricing, mix and efficiency initiatives—should generate more than $20 million of incremental operating income over the remainder of the year, noting upstream cannabis working‑capital issues were remedied after quarter end. In Q1 they reported net revenue of $196.0 million (‑4.4% y/y), gross profit of $53.0 million (‑$3.8M, ‑6.8% y/y) and a consolidated gross‑margin decline of 70 bps; cash of $213.4 million at March 31, 2026 (vs $252.2M at Dec. 31, 2025 that included $12.1M cash in transit); free cash flow of negative $7.6 million (down $6.5M y/y); 2026 share repurchases of 4.5 million shares; $2 million of G&A savings in the quarter; $4.2 million of data‑related revenue; and $3.6 million higher CapEx/lease payments. Segment detail: liquor same‑store sales ‑6.1% and revenue ‑4.9% with a +20‑bp margin improvement; cannabis retail same‑store sales ‑2.5%, gross profit $20.4M (+3.7% y/y) and +100‑bp margin (operating income $1.1M); cannabis operations revenue $29.4M (‑14% y/y), international sales $3.5M (up 94%), contract sales down to $4.5M from $9M, gross margin down ~7 percentage points to 19.7% (from 26.8%) and an operating loss of about $6.9M.

Jeter launch and exclusive U.S. brand partnership

Exclusive contract for production and commercialization of Jeter assumed in April; production and inventory build began in March with initial shipments to provincial boards. Creates an end-to-end cross-border branded platform with potential to drive long-term growth.

Share repurchases and liquidity

Repurchased 4.5 million shares in 2026 under board-approved program. Reported cash of $213.4 million on March 31, 2026 (note: excludes cash-in-transit reclassified under IFRS amendments).

Retail margin expansion and retail profitability

Liquor retail gross margin expanded by 20 basis points; cannabis retail gross margin expanded by 100 basis points; combined retail margin improvement ~50 basis points. Cannabis retail gross profit was $20.4 million (+3.7% YoY) and delivered positive operating income of $1.1 million.

Profit enhancement initiatives and cost savings

Management implemented profit enhancement measures expected to generate more than $20 million of incremental operating income over the remainder of the year. Delivered an additional $2 million in G&A savings during the quarter.

International sales growth and selective retail expansion

International sales increased to $3.5 million (+94% YoY). Expanded cannabis retail footprint by six stores since year-end (including five Canna Cabana locations) and continued rollout of Rise Rewards loyalty program across retail banners.

New revenue streams and data monetization

Data-related revenue reached $4.2 million during the quarter, contributing to diversified revenue channels.

Constructive U.S. regulatory development for SunStream exposure

U.S. regulators moved certain state‑licensed medical marijuana toward Schedule III — a constructive development for SNDL's credit exposure through SunStream and for Parallel, potentially removing 280E tax uncertainty for 2026 and aiding restructure prospects.

SNDL (SNDL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SNDL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2026	2026 (Q2)	>-0.01 / -	0.007	―	―	―
Apr 29, 2026	2026 (Q1)	-0.03 / -0.03	-0.042	33.33% (+0.01)
Mar 12, 2026	2025 (Q4)	0.01 / 0.03	-0.176	116.00% (+0.20)
Nov 04, 2025	2025 (Q3)	0.00 / -0.04	-0.049	28.57% (+0.01)
Jul 31, 2025	2025 (Q2)	-0.04 / <0.01	-0.014	150.00% (+0.02)
May 01, 2025	2025 (Q1)	-0.06 / -0.04	-0.007	-500.00% (-0.04)
Mar 18, 2025	2024 (Q4)	-0.01 / -0.18	-0.233	24.24% (+0.06)
Nov 05, 2024	2024 (Q3)	-0.04 / -0.05	-0.044	-12.90% (>-0.01)
Aug 02, 2024	2024 (Q2)	0.00 / -0.01	-0.066	78.49% (+0.05)
May 09, 2024	2024 (Q1)	-0.04 / >-0.01	-0.073	90.29% (+0.07)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SNDL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 29, 2026	$1.47	$1.31	-10.54%
Mar 12, 2026	$1.54	$1.56	+1.30%
Nov 04, 2025	$2.19	$1.86	-15.07%
Jul 31, 2025	$1.44	$1.72	+19.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.